Medicinova (MNOV) Announces Acceptance of MN-166 ALS Abstract for Presentation at Upcoming ALS/MND Symposium
- Wall Street drops as banks, health stocks weigh
- BAT Reaches Deal to Acquire Reynolds American (RAI) for $49 Billion
- Morgan Stanley (MS) Tops Q4 EPS by 17c
- Trump, Brexit uncertainty hit stocks and dollar, gold jumps
- Pre-Open Stock Movers 01/17: (FWP) (CLSN) (GEVO) Higher; (ADHD) (CBK) (UEC) Lower (more...)
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
MediciNova, Inc. (Nasdaq: MNOV) announced that an abstract regarding MediciNova’s ongoing clinical trial of MN-166 (ibudilast) in ALS has been accepted for oral presentation at the 27th International Symposium on ALS/MND (amyotrophic lateral sclerosis/motor neurone disease) to be held December 7-9, 2016 in Dublin, Ireland.
The presentation entitled "Adaptive Design Single Centre Phosphodiesterase Type 4 (PDE-4) Inhibitor [MN-166 (Ibudilast)] Phase 1b/2a Clinical Trial Double Blind with Open Label Extension for ALS Patients: Interim-blinded Analysis, Behaviour of Creatinine as a Biomarker in Short Clinical Trials [NCT02238626]" will be given by Principal investigator Dr. Benjamin Rix Brooks, Director, Carolinas HealthCare System’s Neuromuscular/ALS-MDA Center.
Presentation details are as follows:
Session Date and Time: Friday, December 9, 2016, 8:50 – 9:10 am
Session: Clinical Trials
Location: Convention Center Dublin (CCD), Spencer Dock, North Wall Quay, Dublin 1, Ireland
About the ALS Trial
MediciNova, in collaboration with Dr. Benjamin Rix Brooks, Director, Carolinas HealthCare System's Neuromuscular/ALS-MDA Center, is currently evaluating MN-166 (ibudilast) in both early and advanced stage ALS patients. This ongoing trial is a randomized, double-blind, placebo-controlled study which includes a six-month treatment period followed by a six-month open-label extension. The study is evaluating several efficacy endpoints including functional activity (ALSFRS-R), respiratory function and muscle strength in subjects with ALS. The study is configured to enroll up to 60 ALS patients without NIV (Non-Invasive Ventilator) and up to 60 ALS patients with NIV.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- iRobot Corp. (IRBT) Names Elisha Finney to Board of Directors
- TRC Cos. (TRR) Acquires NJCEP Contract, Assumes Administrator Role
- ParkerVision (PRKR) Says FBR to Advise on Acquisition Strategy
Create E-mail Alert Related CategoriesCorporate News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!